Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 10/20 | 0.54 |
| ▸ | CSNK1G2 | P78368 | 8/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 8/20 | 0.49 |
| ▸ | GSK3B | P49841 | 7/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CFB | P00751 | 6/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043962 | 0.90 | RAB9A (0.44) | CSNK1DCSNK1G2CSNK1A1GSK3BNPC1 | |
| SCHEMBL1306719 | 0.88 | CSNK1D (0.47) | CSNK1DCSNK1G2CSNK1A1GSK3BPDE10A | |
| SCHEMBL6481602 | 0.88 | RAB9A (0.45) | CSNK1DCSNK1G2CSNK1A1NPC1LMNA | |
| SCHEMBL5048366 | 0.85 | CSNK1D (0.58) | CSNK1DCSNK1G2CSNK1A1GSK3BPDE10A | |
| SCHEMBL5039260 | 0.85 | LMNA (0.42) | CSNK1DCSNK1G2NPC1LMNATP53 | |
| SCHEMBL5039245 | 0.84 | NPC1 (0.42) | CSNK1DCSNK1G2NPC1LMNATP53 | |
| SCHEMBL5047148 | 0.84 | NPC1 (0.42) | CSNK1DCSNK1G2NPC1LMNATP53 | |
| SCHEMBL5044762 | 0.84 | LMNA (0.43) | NPC1LMNATP53MAPTRAB9A | |
| SCHEMBL5410922 | 0.82 | ABL1 (0.52) | NPC1LMNATP53MAPTRAB9A | |
| SCHEMBL5039062 | 0.82 | RAB9A (0.44) | PDE10ANPC1LMNATP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470712-B2 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | claimed |
| JP-2007518809-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1706398-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2006-10-04 | — | — | EP | claimed |
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-15 | — | — | US | claimed |
| WO-2005070920-A1 | AMINO-BENZAZOLES AS P2Y1 RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203146-A1 | Amino-benzazoles as P2Y1 receptor inhibitors | P2RY1, P2RY11, P2RY2 | CSNK1D 1817/4885CSNK1G2 1516/4885CSNK1A1 1196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.